Diabetes Management in the Kidney Patient

Medical Clinics of North America

Volumn 97, Issue 1, 2013, Pages 135-156

  Garg, Rajesh ^a   Williams, Mark E ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b JOSLIN DIABETES CENTER   (United States)

Author keywords

Chronic kidney disease; Diabetes; Hyperglycemia

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; BROMOCRIPTINE; COLESEVELAM; EXENDIN 4; FRUCTOSAMINE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCOSE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE;

ALBUMIN BLOOD LEVEL; ALBUMINURIA; CHRONIC KIDNEY DISEASE; CONSTIPATION; CYANOCOBALAMIN DEFICIENCY; DIABETES CONTROL; DIABETES MELLITUS; DIZZINESS; DRUG MECHANISM; EDEMA; FATIGUE; FRACTURE; FRUCTOSAMINE BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; KIDNEY FAILURE; LACTIC ACIDOSIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THYROID CANCER; URTICARIA; VOMITING; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG MONITORING; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; KIDNEY; KIDNEY FUNCTION TESTS; METABOLIC CLEARANCE RATE; OUTCOME ASSESSMENT (HEALTH CARE); RENAL INSUFFICIENCY, CHRONIC; RISK ADJUSTMENT;

EID: 84871803173     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2012.11.001     Document Type: Review

References (110)

1. Mak R.H. Impact of end-stage renal disease and dialysis on glycemic control. Semin Dial 2000, 13(1):4-8.
2. Akmal M., Massry S.G., Goldstein D.A., et al. Role of parathyroid hormone in the glucose intolerance of chronic renal failure. J Clin Invest 1985, 75(3):1037-1044.
3. Mak R.H. Intravenous 1,25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients. Kidney Int 1992, 41(4):1049-1054.
4. Viswanathan V., Tilak P., Meerza R., et al. Insulin resistance at different stages of diabetic kidney disease in India. J Assoc Physicians India 2010, 58:612-615.
5. Alvestrand A. Carbohydrate and insulin metabolism in renal failure. Kidney Int Suppl 1997, 62:S48-S52.
6. Goldstein B.J., Mahadev K., Wu X. Redox paradox: insulin action is facilitated by insulin-stimulated reactive oxygen species with multiple potential signaling targets. Diabetes 2005, 54(2):311-321.
7. Chang G.Y., Park A.S., Susztak K. Tracing the footsteps of glomerular insulin signaling in diabetic kidney disease. Kidney Int 2011, 79(8):802-804.
8. Hager S.R. Insulin resistance of uremia. Am J Kidney Dis 1989, 14(4):272-276.
9. Smith D., DeFronzo R.A. Insulin resistance in uremia mediated by postbinding defects. Kidney Int 1982, 22(1):54-62.
10. Fliser D., Pacini G., Engelleiter R., et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 1998, 53(5):1343-1347.
11. DeFronzo R.A., Tobin J.D., Rowe J.W., et al. Glucose intolerance in uremia. Quantification of pancreatic beta cell sensitivity to glucose and tissue sensitivity to insulin. J Clin Invest 1978, 62(2):425-435.
12. Schmitz O. Insulin-mediated glucose uptake in nondialyzed and dialyzed uremic insulin-dependent diabetic subjects. Diabetes 1985, 34(11):1152-1159.
13. Manolescu B., Stoian I., Atanasiu V., et al. Review article: the role of adipose tissue in uraemia-related insulin resistance. Nephrology (Carlton) 2008, 13(7):622-628.
14. Lim P.S., Chen S.L., Wu M.Y., et al. Association of plasma adiponectin levels with oxidative stress in hemodialysis patients. Blood Purif 2007, 25(4):362-369.
15. Guo L.L., Pan Y., Jin H.M. Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. Nephrol Dial Transplant 2009, 24(6):1876-1883.
16. Zanetti M., Barazzoni R., Guarnieri G. Inflammation and insulin resistance in uremia. J Ren Nutr 2008, 18(1):70-75.
17. Khedr E., El-Sharkawy M., Abdulwahab S., et al. Effect of recombinant human erythropoietin on insulin resistance in hemodialysis patients. Hemodial Int 2009, 13(3):340-346.
18. Adrogue H.J. Glucose homeostasis and the kidney. Kidney Int 1992, 42(5):1266-1282.
19. Goecke I.A., Bonilla S., Marusic E.T., et al. Enhanced insulin sensitivity in extrarenal potassium handling in uremic rats. Kidney Int 1991, 39(1):39-43.
20. Ikizler T.A. Effects of glucose homeostasis on protein metabolism in patients with advanced chronic kidney disease. J Ren Nutr 2007, 17(1):13-16.
21. Cusi K., Maezono K., Osman A., et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000, 105(3):311-320.
22. Siew E.D., Ikizler T.A. Insulin resistance and protein energy metabolism in patients with advanced chronic kidney disease. Semin Dial 2010, 23(4):378-382.
23. Siew E.D., Pupim L.B., Majchrzak K.M., et al. Insulin resistance is associated with skeletal muscle protein breakdown in non-diabetic chronic hemodialysis patients. Kidney Int 2007, 71(2):146-152.
24. Mather A., Pollock C. Glucose handling by the kidney. Kidney Int Suppl 2011, (120):S1-S6.
25. List J.F., Whaley J.M. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans. Kidney Int Suppl 2011, (120):S20-S27.
26. Jurczak M.J., Lee H.Y., Birkenfeld A.L., et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 2011, 60(3):890-898.
27. Ahmed M.H. The kidneys as an emerging target for the treatment of diabetes mellitus: what we know, thought we knew and hope to gain. Int J Diabetes Mellit 2010, 2(2):125-126.
28. Liu J.J., Lee T., Defronzo R.A. Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?. Diabetes 2012, 61(9):2199-2204.
29. Mima A., Ohshiro Y., Kitada M., et al. Glomerular-specific protein kinase C-beta-induced insulin receptor substrate-1 dysfunction and insulin resistance in rat models of diabetes and obesity. Kidney Int 2011, 79(8):883-896.
30. Dunn P.J., Cole R.A., Soeldner J.S., et al. Reproducibility of hemoglobin AIc and sensitivity to various degrees of glucose intolerance. Ann Intern Med 1979, 91(3):390-396.
31. Rohlfing C.L., Wiedmeyer H.M., Little R.R., et al. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care 2002, 25(2):275-278.
32. Nathan D.M., Kuenen J., Borg R., et al. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008, 31(8):1473-1478.
33. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321(7258):405-412.
34. Rubinow K.B., Hirsch I.B. Reexamining metrics for glucose control. JAMA 2011, 305(11):1132-1133.
35. Holt R.I., Gallen I. Time to move beyond glycosylated haemoglobin. Diabet Med 2004, 21(7):655-656.
36. Ly J., Marticorena R., Donnelly S. Red blood cell survival in chronic renal failure. Am J Kidney Dis 2004, 44(4):715-719.
37. Little R.R., Tennill A.L., Rohlfing C., et al. Can glycohemoglobin be used to assess glycemic control in patients with chronic renal failure?. Clin Chem 2002, 48(5):784-786.
38. Brown J.N., Kemp D.W., Brice K.R. Class effect of erythropoietin therapy on hemoglobin A(1c) in a patient with diabetes mellitus and chronic kidney disease not undergoing hemodialysis. Pharmacotherapy 2009, 29(4):468-472.
39. KDOQI KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007, 49(2):S12-S154.
40. Cohen R.M., Smith E.P. Frequency of HbA1c discordance in estimating blood glucose control. Curr Opin Clin Nutr Metab Care 2008, 11(4):512-517.
41. U S Renal Data System USRDS 2008 annual data report: atlas of end-stage renal disease in the United States 2008, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD).
42. Williams M.E., Lacson E., Teng M., et al. Hemodialyzed type I and type II diabetic patients in the US: characteristics, glycemic control, and survival. Kidney Int 2006, 70(8):1503-1509.
43. Peacock T.P., Shihabi Z.K., Bleyer A.J., et al. Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int 2008, 73(9):1062-1068.
44. Chen H.S., Wu T.E., Lin H.D., et al. Hemoglobin A(1c) and fructosamine for assessing glycemic control in diabetic patients with CKD stages 3 and 4. Am J Kidney Dis 2010, 55(5):867-874.
45. Riveline J.P., Teynie J., Belmouaz S., et al. Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system. Nephrol Dial Transplant 2009, 24(9):2866-2871.
46. Ansari A., Thomas S., Goldsmith D. Assessing glycemic control in patients with diabetes and end-stage renal failure. Am J Kidney Dis 2003, 41(3):523-531.
47. Mittman N., Desiraju B., Fazil I., et al. Serum fructosamine versus glycosylated hemoglobin as an index of glycemic control, hospitalization, and infection in diabetic hemodialysis patients. Kidney Int Suppl 2010, (117):S41-S45.
48. Inaba M., Okuno S., Kumeda Y., et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007, 18(3):896-903.
49. Alskar O., Korell J., Duffull S.B. A pharmacokinetic model for the glycation of albumin. J Pharmacokinet Pharmacodyn 2012, 39(3):273-282.
50. Abe M., Matsumoto K. Glycated hemoglobin or glycated albumin for assessment of glycemic control in hemodialysis patients with diabetes?. Nat Clin Pract Nephrol 2008, 4(9):482-483.
51. Freedman B.I., Andries L., Shihabi Z.K., et al. Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients. Clin J Am Soc Nephrol 2011, 6(7):1635-1643.
52. Inzucchi S.E., Bergenstal R.M., Buse J.B., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35(6):1364-1379.
53. O'Toole S.M., Fan S.L., Yaqoob M.M., et al. Managing diabetes in dialysis patients. Postgrad Med J 2012, 88(1037):160-166.
54. Kalantar-Zadeh K., Kopple J.D., Regidor D.L., et al. A1C and survival in maintenance hemodialysis patients. Diabetes Care 2007, 30(5):1049-1055.
55. Williams M.E., Lacson E., Wang W., et al. Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent Cox model analyses. Clin J Am Soc Nephrol 2010, 5(9):1595-1601.
56. Ix J.H. Hemoglobin A1c in hemodialysis patients: should one size fit all?. Clin J Am Soc Nephrol 2010, 5(9):1539-1541.
57. Ramirez S.P., McCullough K.P., Thumma J.R., et al. Hemoglobin A1c levels and mortality in the diabetic hemodialysis population: findings from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Diabetes Care 2012.
58. Drechsler C., Krane V., Ritz E., et al. Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation 2009, 120(24):2421-2428.
59. Shurraw S., Hemmelgarn B., Lin M., et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med 2011, 171(21):1920-1927.
60. Lachin J.M., Viberti G., Zinman B., et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clin J Am Soc Nephrol 2011, 6(5):1032-1040.
61. American Diabetes Association Standards of medical care in diabetes-2012. Diabetes Care 2012, 35(Suppl 1):S11-S63.
62. Amiel S.A., Dixon T., Mann R., et al. Hypoglycaemia in type 2 diabetes. Diabet Med 2008, 25(3):245-254.
63. Munshi M.N., Segal A.R., Suhl E., et al. Frequent hypoglycemia among elderly patients with poor glycemic control. Arch Intern Med 2011, 171(4):362-364.
64. Gerstein H.C., Miller M.E., Byington R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358(24):2545-2559.
65. Patel A., MacMahon S., Chalmers J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358(24):2560-2572.
66. Duckworth W., Abraira C., Moritz T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360(2):129-139.
67. Haviv Y.S., Sharkia M., Safadi R. Hypoglycemia in patients with renal failure. Ren Fail 2000, 22(2):219-223.
68. Sun C.Y., Lee C.C., Wu M.S. Hypoglycemia in diabetic patients undergoing chronic hemodialysis. Ther Apher Dial 2009, 13(2):95-102.
69. Williams M.E., Lacson E., Wang W. High glucose variability increases risk of all-cause and hypoglycemia-related hospitalization in diabetic chronic hemodialysis patients (abstract). J Am Soc Nephrol 2009, 20:193A.
70. Vallurupalli S., Huesmann G., Gregory J., et al. Levofloxacin-associated hypoglycaemia complicated by pontine myelinolysis and quadriplegia. Diabet Med 2008, 25(7):856-859.
71. Zoungas S., Chalmers J., Ninomiya T., et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia 2012, 55(3):636-643.
72. O'Keefe J.H., Abuannadi M., Lavie C.J., et al. Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus. Mayo Clin Proc 2011, 86(2):128-138.
73. Nathan D.M., Buse J.B., Davidson M.B., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32(1):193-203.
74. Rodbard H.W., Jellinger P.S., Davidson J.A., et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009, 15(6):540-559.
75. Qaseem A., Humphrey L.L., Sweet D.E., et al. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2012, 156(3):218-231.
76. Bennett W.L., Odelola O.A., Wilson L.M., et al. Evaluation of guideline recommendations on oral medications for type 2 diabetes mellitus: a systematic review. Ann Intern Med 2012, 156(1 Pt 1):27-36.
77. Kahn S.E., Haffner S.M., Heise M.A., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355(23):2427-2443.
78. Schejter Y.D., Turvall E., Ackerman Z. Characteristics of patients with sulphonurea-induced hypoglycemia. J Am Med Dir Assoc 2012, 13(3):234-238.
79. Holstein A., Plaschke A., Hammer C., et al. Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia. Eur J Clin Pharmacol 2003, 59(2):91-97.
80. Rosenkranz B., Profozic V., Metelko Z., et al. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia 1996, 39(12):1617-1624.
81. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352(9131):854-865.
82. Holman R.R., Paul S.K., Bethel M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359(15):1577-1589.
83. Runge S., Mayerle J., Warnke C., et al. Metformin-associated lactic acidosis in patients with renal impairment solely due to drug accumulation?. Diabetes Obes Metab 2008, 10(1):91-93.
84. Pongwecharak J., Tengmeesri N., Malanusorn N., et al. Prescribing metformin in type 2 diabetes with a contraindication: prevalence and outcome. Pharm World Sci 2009, 31(4):481-486.
85. Abe M., Okada K., Maruyama T., et al. Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis. Expert Opin Pharmacother 2010, 11(10):1611-1620.
86. Agrawal A., Sautter M.C., Jones N.P. Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: a post hoc analysis. Clin Ther 2003, 25(11):2754-2764.
87. Chiang C.K., Ho T.I., Peng Y.S., et al. Rosiglitazone in diabetes control in hemodialysis patients with and without viral hepatitis infection: effectiveness and side effects. Diabetes Care 2007, 30(1):3-7.
88. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356(24):2457-2471.
89. Ramirez S.P., Albert J.M., Blayney M.J., et al. Rosiglitazone is associated with mortality in chronic hemodialysis patients. J Am Soc Nephrol 2009, 20(5):1094-1101.
90. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366(9493):1279-1289.
91. Schneider C.A., Ferrannini E., Defronzo R., et al. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol 2008, 19(1):182-187.
92. Habib Z.A., Havstad S.L., Wells K., et al. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010, 95(2):592-600.
93. Lewis J.D., Ferrara A., Peng T., et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011, 34(4):916-922.
94. Chan J.C., Scott R., Arjona Ferreira J.C., et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008, 10(7):545-555.
95. Graefe-Mody U., Friedrich C., Port A., et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin((*). Diabetes Obes Metab 2011, 13(10):939-946.
96. Lukashevich V., Schweizer A., Shao Q., et al. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab 2011, 13(10):947-954.
97. Nowicki M., Rychlik I., Haller H., et al. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract 2011, 65(12):1230-1239.
98. Nowicki M., Rychlik I., Haller H., et al. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab 2011, 13(6):523-532.
99. Linnebjerg H., Kothare P.A., Park S., et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007, 64(3):317-327.
100. Kaakeh Y., Kanjee S., Boone K., et al. Liraglutide-induced acute kidney injury. Pharmacotherapy 2012, 32(1):e7-11.
101. Lopez-Ruiz A., del Peso-Gilsanz C., Meoro-Aviles A., et al. Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers. Pharm World Sci 2010, 32(5):559-561.
102. Devineni D., Walter Y.H., Smith H.T., et al. Pharmacokinetics of nateglinide in renally impaired diabetic patients. J Clin Pharmacol 2003, 43(2):163-170.
103. Inoue T., Shibahara N., Miyagawa K., et al. Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. Clin Nephrol 2003, 60(2):90-95.
104. Rave K., Heise T., Pfutzner A., et al. Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. Diabetes Care 2001, 24(5):886-890.
105. Baldwin D., Zander J., Munoz C., et al. A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency. Diabetes Care 2012, 35(10):1970-1974.
106. Sobngwi E., Enoru S., Ashuntantang G., et al. Day-to-day variation of insulin requirements of patients with type 2 diabetes and end-stage renal disease undergoing maintenance hemodialysis. Diabetes Care 2010, 33(7):1409-1412.
107. Aisenpreis U., Pfutzner A., Giehl M., et al. Pharmacokinetics and pharmacodynamics of insulin Lispro compared with regular insulin in haemodialysis patients with diabetes mellitus. Nephrol Dial Transplant 1999, 14(Suppl 4):5-6.
108. Czock D., Aisenpreis U., Rasche F.M., et al. Pharmacokinetics and pharmacodynamics of lispro-insulin in hemodialysis patients with diabetes mellitus. Int J Clin Pharmacol Ther 2003, 41(10):492-497.
109. Holmes G., Galitz L., Hu P., et al. Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. Br J Clin Pharmacol 2005, 60(5):469-476.
110. Hung A.M., Roumie C.L., Greevy R.A., et al. Comparative effectiveness of incident oral antidiabetic drugs on kidney function. Kidney Int 2012, 81(7):698-706.